Literature DB >> 32655711

Medium- and long-term functional behavior evaluations in an experimental focal ischemic stroke mouse model.

Juçara Loli de Oliveira1, Marina Ávila2, Thiago Cesar Martins2, Marcio Alvarez-Silva3, Elisa Cristiana Winkelmann-Duarte1, Afonso Shiguemi Inoue Salgado2,4,5, Francisco José Cidral-Filho2,4, William R Reed6, Daniel F Martins2,4.   

Abstract

Cerebrovascular accident (CVA) is one of the leading causes of death and disability worldwide, as well as a major financial burden for health care systems. CVA rodent models provide experimental support to determine possible in vivo therapies to reduce brain injury and consequent sequelae. This study analyzed nociceptive, motor, cognitive and mood functions in mice submitted to distal middle cerebral artery (DMCA) occlusion. Male C57BL mice (n = 8) were randomly allocated to control or DMCA groups. Motor function was evaluated with the tests: grip force, rotarod and open field; and nociceptive threshold with von Frey and hot plate assessments. Cognitive function was evaluated with the inhibitory avoidance test, and mood with the tail suspension test. Evaluations were conducted on the seventh- and twenty-eighth-day post DMCA occlusion to assess medium- and long-term effects of the injury, respectively. DMCA occlusion significantly decreases muscle strength and spontaneous locomotion (p < 0.05) both medium- and long term; as well as increases immobility in the tail-suspension test (p < 0.05), suggesting a depressive-type behavior. However, DMCA occlusion did not affect nociceptive threshold nor cognitive functions (p > 0.05). These results suggest that, medium- and long-term effects of DMCA occlusion include motor function impairments, but no sensory dysfunction. Additionally, the injury affected mood but did not hinder cognitive function. © Springer Nature B.V. 2020.

Entities:  

Keywords:  Locomotor activity; Motor deficit; Neuroscience; Sensory deficit; Stroke

Year:  2020        PMID: 32655711      PMCID: PMC7334328          DOI: 10.1007/s11571-020-09584-8

Source DB:  PubMed          Journal:  Cogn Neurodyn        ISSN: 1871-4080            Impact factor:   5.082


  41 in total

1.  Long-Term Regular Eccentric Exercise Decreases Neuropathic Pain-like Behavior and Improves Motor Functional Recovery in an Axonotmesis Mouse Model: the Role of Insulin-like Growth Factor-1.

Authors:  Daniel F Martins; Thiago C Martins; Ana Paula Batisti; Larissa Dos Santos Leonel; Franciane Bobinski; Luiz A O Belmonte; Leidiane Mazzardo-Martins; Eduardo Cargnin-Ferreira; Adair R S Santos
Journal:  Mol Neurobiol       Date:  2017-12-18       Impact factor: 5.590

Review 2.  Influence of pharmacological and epigenetic factors to suppress neurotrophic factors and enhance neural plasticity in stress and mood disorders.

Authors:  Shashikanta Tarai; Rupsha Mukherjee; Sharda Gupta; Albert A Rizvanov; Andras Palotás; V S Chandrasekhar Pammi; Arindam Bit
Journal:  Cogn Neurodyn       Date:  2019-02-01       Impact factor: 5.082

3.  Functional testing in a mouse stroke model induced by occlusion of the distal middle cerebral artery.

Authors:  Judith Lubjuhn; Alexandra Gastens; Gertrud von Wilpert; Panagiotis Bargiotas; Oliver Herrmann; Sasidhar Murikinati; Tamer Rabie; Hugo H Marti; Hugo Marti; Ivo Amende; Tom G Hampton; Markus Schwaninger
Journal:  J Neurosci Methods       Date:  2009-08-04       Impact factor: 2.390

4.  Depression after stroke: results of the FINNSTROKE Study.

Authors:  M Kotila; H Numminen; O Waltimo; M Kaste
Journal:  Stroke       Date:  1998-02       Impact factor: 7.914

5.  Optimal blood glucose levels while using insulin to minimize the size of infarction in focal cerebral ischemia.

Authors:  Chang Z Zhu; Roland N Auer
Journal:  J Neurosurg       Date:  2004-10       Impact factor: 5.115

6.  Social interaction improves experimental stroke outcome.

Authors:  Tara K S Craft; Erica R Glasper; Louise McCullough; Ning Zhang; Nobuo Sugo; Takashi Otsuka; Patricia D Hurn; A Courtney DeVries
Journal:  Stroke       Date:  2005-08-11       Impact factor: 7.914

7.  Two-year longitudinal study of poststroke mood disorders: diagnosis and outcome at one and two years.

Authors:  R G Robinson; P L Bolduc; T R Price
Journal:  Stroke       Date:  1987 Sep-Oct       Impact factor: 7.914

Review 8.  An overview of animal models of pain: disease models and outcome measures.

Authors:  Nicholas S Gregory; Amber L Harris; Caleb R Robinson; Patrick M Dougherty; Perry N Fuchs; Kathleen A Sluka
Journal:  J Pain       Date:  2013-09-12       Impact factor: 5.820

Review 9.  Update of the stroke therapy academic industry roundtable preclinical recommendations.

Authors:  Marc Fisher; Giora Feuerstein; David W Howells; Patricia D Hurn; Thomas A Kent; Sean I Savitz; Eng H Lo
Journal:  Stroke       Date:  2009-02-26       Impact factor: 7.914

10.  Prevalence of depression after stroke: the Perth Community Stroke Study.

Authors:  P W Burvill; G A Johnson; K D Jamrozik; C S Anderson; E G Stewart-Wynne; T M Chakera
Journal:  Br J Psychiatry       Date:  1995-03       Impact factor: 9.319

View more
  3 in total

1.  Changes in Brain Functional Network Connectivity in Adult Moyamoya Diseases.

Authors:  Gaoxing Zheng; Yu Lei; Yuzhu Li; Wei Zhang; Jiabin Su; Xiaoying Qi; Liang Chen; Xin Zhang; Yuxiang Gu; Yuguo Yu; Ying Mao
Journal:  Cogn Neurodyn       Date:  2021-02-07       Impact factor: 3.473

2.  Isofuranodiene, a Natural Sesquiterpene Isolated from Wild Celery (Smyrnium olusatrum L.), Protects Rats against Acute Ischemic Stroke.

Authors:  Hasan Yousefi-Manesh; Ahmad Reza Dehpour; Samira Shirooie; Fariba Bagheri; Vida Farrokhi; Seyyedeh Elaheh Mousavi; Massimo Ricciutelli; Loredana Cappellacci; Víctor López; Filippo Maggi; Riccardo Petrelli
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-09

3.  Cross-frequency and iso-frequency estimation of functional corticomuscular coupling after stroke.

Authors:  Ping Xie; Xiaohui Pang; Shengcui Cheng; Yuanyuan Zhang; Yinan Yang; Xiaoli Li; Xiaoling Chen
Journal:  Cogn Neurodyn       Date:  2020-09-16       Impact factor: 3.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.